In vivo targeting of dendritic cells in lymph nodes with poly(propylene sulfide) nanoparticles

被引:558
作者
Reddy, ST
Rehor, A
Schmoekel, HG
Hubbell, JA
Swartz, MA
机构
[1] Ecole Polytech Fed Lausanne, Inst Bioengn, Lab Mechanol & Morphogenesis, CH-1015 Lausanne, Switzerland
[2] FU Berlin, Polyclin Small Anim Med, D-14163 Berlin, Germany
关键词
antigen-presenting cells; vaccines; immunotherapy; macrophages;
D O I
10.1016/j.jconrel.2006.01.006
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Delivery of biodegradable nanoparticles to antigen-presenting cells (APCs), specifically dendritic cells (DCs), has potential for immunotherapy. This study investigates the delivery of 20, 45, and 100nm diameter poly(ethylene glycol)-stabilized poly(propylene sulfide) (PPS) nanoparticles to DCs in the lymph nodes. These nanoparticles consist of a cross-linked rubbery core of PPS surrounded by a hydrophilic corona of poly(ethylene glycol). The PPS domain is capable of carrying hydrophobic drugs and degrades within oxidative environments. 20 nm particles were most readily taken up into lymphatics following interstitial injection, while both 20 and 45nm nanoparticles showed significant retention in lymph nodes, displaying a consistent and strong presence at 24, 72, 96 and 120h post-injection. Nanoparticles were internalized by up to 40-50% of lymph node DCs (and APCs) without the use of a targeting ligand, and the site of internalization was in the lymph nodes rather than at the injection site. Finally, an increase in nanoparticle-containing DCs (and other APCs) was seen at 96h vs. 24h, suggesting an infiltration of these cells to lymph nodes. Thus, PPS nanoparticles of 20-45nm have the potential for immunotherapeutic applications that specifically target DCs in lymph nodes. (c) 2006 Elsevier B.V. All rights reserved.
引用
收藏
页码:26 / 34
页数:9
相关论文
共 58 条
[1]   SUBCUTANEOUS ADMINISTRATION OF LIPOSOMES - A COMPARISON WITH THE INTRAVENOUS AND INTRAPERITONEAL ROUTES OF INJECTION [J].
ALLEN, TM ;
HANSEN, CB ;
GUO, LSS .
BIOCHIMICA ET BIOPHYSICA ACTA, 1993, 1150 (01) :9-16
[2]   Dyslipidemia associated with atherosclerotic disease systemically alters dendritic cell mobilization [J].
Angeli, V ;
Llodrá, J ;
Rong, JX ;
Satoh, K ;
Ishii, S ;
Shimizu, T ;
Fisher, EA ;
Randolph, GJ .
IMMUNITY, 2004, 21 (04) :561-574
[3]   Dendritic cells and the control of immunity [J].
Banchereau, J ;
Steinman, RM .
NATURE, 1998, 392 (6673) :245-252
[4]   Transport in lymphatic capillaries .2. Microscopic velocity measurement with fluorescence photobleaching [J].
Berk, DA ;
Swartz, MA ;
Leu, AJ ;
Jain, RK .
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY, 1996, 270 (01) :H330-H337
[5]   Efficient targeting of protein antigen to the dendritic cell receptor DEC-205 in the steady state leads to antigen presentation on major histocompatibility complex class I products and peripheral CD8+ T cell tolerance [J].
Bonifaz, L ;
Bonnyay, D ;
Mahnke, K ;
Rivera, M ;
Nussenzweig, MC ;
Steinman, RM .
JOURNAL OF EXPERIMENTAL MEDICINE, 2002, 196 (12) :1627-1638
[6]   In vivo targeting of antigens to maturing dendritic cells via the DEC-205 receptor improves T cell vaccination [J].
Bonifaz, LC ;
Bonnyay, DP ;
Charalambous, A ;
Darguste, DI ;
Fujii, SI ;
Soares, H ;
Brimnes, MK ;
Moltedo, B ;
Moran, TM ;
Steinman, RM .
JOURNAL OF EXPERIMENTAL MEDICINE, 2004, 199 (06) :815-824
[7]   DENDRITIC CELLS OF THE MOUSE RECOGNIZED BY 2 MONOCLONAL-ANTIBODIES [J].
BREEL, M ;
MEBIUS, RE ;
KRAAL, G .
EUROPEAN JOURNAL OF IMMUNOLOGY, 1987, 17 (11) :1555-1559
[8]   Liposomal delivery of antigen to human dendritic cells [J].
Copland, MJ ;
Baird, MA ;
Rades, T ;
McKenzie, JL ;
Becker, B ;
Reck, F ;
Tyler, PC ;
Davies, NM .
VACCINE, 2003, 21 (9-10) :883-890
[9]   Chemokines - Chemokines and cell migration in secondary lymphoid organs [J].
Cyster, JG .
SCIENCE, 1999, 286 (5447) :2098-2102
[10]   Phagocytosis stimulates alternative glycosylation of macrosialin (mouse CD68), a macrophage-specific endosomal protein [J].
da Silva, RP ;
Gordon, S .
BIOCHEMICAL JOURNAL, 1999, 338 :687-694